LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6

Benzinga Newsdesk www.benzinga.com Positive 61.9%

Neg 0% Neu 0% Pos 61.9%

LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.